In a First for Pharma, Citeline SmartSolutions Take AI to New Levels, Optimizing Clinical Trial Planning and Site Selection
Globe Newswire13-08-2024, 20:00
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26